Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Advertisement

Close

AACR Journals
For Authors
About Us
Article Collections
Cancer Hallmarks
Webinars

header search

search input Search input auto suggest

Search

Advanced Search

Menu

About
Articles
First Disclosures
For Authors
Alerts
News
Cancer Hallmarks
Webinars

Skip Nav Destination

Current Issue

Volume 22,

Issue 12

1 December 2023

View This Issue

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

5.7

SUBMIT TO JOURNAL

Featured Articles

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Neil A. O'Brien, et al.

Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition

Satish Kumar R. Noonepalle, et al.

Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor

Kathryn M. Lemberg, et al.

Trending - Altmetric

The article titled, Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor, has an Alt Metric Attention Score of 23.2. Click to see more of this article's metrics.

Read the article titled, Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor

Last mentioned on Sunday December 3 2023

The article titled, Abstract C169: AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage to elicit tumor cell kill, has an Alt Metric Attention Score of 6.95. Click to see more of this article's metrics.

Read the article titled, Abstract C169: AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage to elicit tumor cell kill

Last mentioned on Sunday December 3 2023

Latest
Most Read
Most Cited

Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability

Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors

Abstract PR005: Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis

Abstract PR004: PRISM high-throughput screening of antibody-drug conjugates uncovers clinically relevant targets

The Twitter live feed is not currently active.

Keep up to date with Molecular Cancer Therapeutics

Follow @MCT_AACR

Issues
Online First
News

Twitter

Online ISSN 1538-8514
Print ISSN 1535-7163

AACR Journals

Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics

Info for Advertisers
Information for Institutions/Librarians
Privacy Policy

Twitter
LinkedIn
Facebook
Youtube

Copyright © 2023 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept